PARPi

From the Field

Real-world Utilization of Second-line Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy Versus Active Surveillance in Community Oncology Practice Patients With Advanced Ovarian Cancer

05/19/2022

Robert Reid, MD

Yiqiong Xie, PhD, MPH

Junxin Shi, PhD

Katrine L Wallace, PhD

Dr Wallace and colleagues analyzed second-line poly(ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy in a real-world setting to understand how it is being utilized and the resultant impact on patients’ disease course.

Dr Wallace and colleagues...

05/19/2022

Journal of Clinical Pathways

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

September 21 ⁠–⁠ September 22

September 30 ⁠–⁠ October 2

October 1 ⁠–⁠ October 2

October 2 ⁠–⁠ October 5

October 5 ⁠–⁠ October 6

October 14 ⁠–⁠ October 16

October 16 ⁠–⁠ October 19

October 19 ⁠–⁠ October 20

October 26 ⁠–⁠ October 27

October 29 ⁠–⁠ November 2

See Full Calendar

PARPi

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products